Drugs / LC-CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03353428 | Nov 2017 → Jan 2019 | non-small cell lung carcinoma | Shenzhen Geno-Immune Medical Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC-CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03353428 ↗ |
| Modality | Cell therapy | “Autologous lung cancer specific cytotoxic lymphocytes” NCT03353428 ↗ |
| Route | Intravenous | “via IV” NCT03353428 ↗ |